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The presence of circulating autoantibodies, primarily to complement factor H (CFH-
Ab) in plasma characterizes the autoimmune form of atypical hemolytic uremic 
syndrome (aHUS). This acquired form of aHUS defines a distinct subgroup of aHUS 
patients, which requires diagnostic and treatment approaches in part different from 
those of the genetically defined forms. The mechanisms leading to CFH-Ab 
production and disease onset are not completely understood, but CFH-Ab HUS 
seems to be secondary to a combination of genetic predisposition and environmental 
factors. Early diagnosis of this specific aHUS entity is important, as prompt induction 
of plasma exchange and concomitant immunosuppression leads to a favourable 
outcome. Nevertheless, information on clinical features and outcome in children is 
limited. Here, we review the literature on the biological and clinical features of CFH-
















Hemolytic uremic syndrome (HUS) generally indicates a multisystemic disease 
process, characterized by Coombs-negative (except for pneumococcal-HUS) 
hemolytic anemia, thrombocytopenia and acute renal failure. 
Atypical HUS  (aHUS) represents a heterogeneous group of disorders not associated 
with infection by Shiga toxin producing E.coli (eHUS) [1]. Prognosis is poor with high 
risk of recurrence and about 50% of cases progress to end-stage renal failure [2,3]. 
Atypical HUS can occur in all age groups, with sporadic and familial presentations [4].  
It has been shown that dysregulation of the complement alternative pathway (AP) is 
the major pathophysiological mechanism leading to aHUS [5]. Overactivation of the 
complement system leads to endothelial damage and microvascular thrombosis [6]. 
This is facilitated by mutations in genes coding for complement proteins (complement 
factor H (CFH) [7-12], membrane cofactor protein (MCP) [13-15], factor I (CFI) [16-
18], factor B [19], C3 [20] or thrombomodulin [21]), or by antibodies against the 
complement regulatory proteins CFH and CFI [22-24]. 
CFI antibodies were described in three aHUS patients in one single study [24]. 
However, their functional significance and disease causing and/or promoting 
potential remained unclear as two of those patients had additional functionally 
significant mutations in CFH [24]. 
Antibodies against the alternative complement pathway regulator CFH (CFH-Ab) 
have been reported in aHUS patients [22,23]. These antibodies are able to induce 
functional CFH deficiency [22,23,25]. Interestingly, several studies [23,26-31] 
established a specific relationship between deficiency of factor H-related protein 1 
(CFHR1) and the generation of CFH-Ab as discussed in detail later in this article. 
Data on clinical and biological features are available in the form of several case 
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reports, small case series and only two bigger cohorts [22,23,26-43]. However, clear 
data and prospective trials to determine the optimal treatment modalities are lacking.  
CFH-Ab are not only described in the setting of aHUS but also in post hematopoietic 
stem cell transplant (HSCT) thrombotic microangiopathy (TMA). One out of 3 patients 
with TMA following allogeneic HSCT developed CFH-Ab, potentially as a form of 
“autoimmune” reaction to genotypic differences between recipient and donor [44,45].  
Moreover, CFH-Ab may play a significant role in a subgroup of patients with 
membranoproliferative glomerulonephritis (MPGN). Goodship et al. [46] described 
two patients with MPGN with a high titre of functionally significant CFH-Ab and 
suggested that antibody depleting therapy may have a role in such patients and that 
screening for CFH-Ab should be undertaken in all patients with MPGN. Similarly, in a 
patient with dense deposit disease, CFH-Ab in context with monoclonal gammopathy 
was described [47,48]. In addition, CFH-Ab are described in the setting of systemic 
lupus erythematodes (6.7%), rheumatoid arthritis (9.2% - 16.5%) and thrombosis 
patients positive for the lupus anticoagulants test (9.4%) [49]. 
Strikingly, Dhillon et al. [50] found, by using an autoantibody threshold derived from 
the mean+2 SD of samples of blood donor control subjects, that CFH-Ab are present 
in at least 1% of healthy blood donors. Zadura et al. [49] describe up to 4% of healthy 
individuals as CFH-Ab positive. Nevertheless, those CFH-Ab in healthy individuals 
show different characteristics than most of those described in CFH-Ab aHUS [49,50]. 
In this review we summarize and discuss the existing experimental and clinical data 
on this particular autoimmune form of aHUS. 
 
Detection and types of CFH-Ab 
The established method to identify CFH-Ab HUS uses ELISA with purified CFH 
immobilized on microtiter plates and anti-human IgG antibody for detection of 
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autoantibody binding [22,51]. Thus, the assay that is now commonly used measures 
free (i.e., not in complex with CFH in patient plasma) autoantibodies of the IgG 
isotype. In a few studies, further analyses were performed and the majority of 
analyzed patients had IgG3 and/or IgG1 autoantibodies [22,23,29,52]. In addition, in 
three patients, IgA class autoantibodies were found together with IgG [53].  
Depending on the amount and affinity of circulating autoantibodies, a substantial part 
of the antibodies is in complex with CFH. These immune complexes can be detected 
using anti-CFH polyclonal or monoclonal antibodies (mAb) as capture antibodies in 
ELISA [29]. The mAb should be carefully chosen to bind to a different domain than 
the autoantibody to avoid false negative results. The titer of CFH-Ab complexes 
correlates better with disease severity than the free antibody titer [34].  
It should be noted that because of individual differences among the patients 
regarding the exact epitope, isotype and affinity of the autoantibodies, the antibody 
titers cannot be directly compared between patients and a clear cut-off for the level of 
disease-causing antibodies cannot be established. The course of titer changes in 
single patients is, however, informative and useful during follow-up in making 
decisions on treatment. 
It is also important to keep in mind that, when determining the CFH antigen level in 
the patients, the autoantibodies may interfere with the measurement if they bind to 
the same site on CFH as the monoclonal antibody used in the CFH ELISA [29,53], 




Genetics of CFH-Ab HUS 
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As in many autoimmune diseases, genetic factors increase the susceptibility for 
developing aHUS. The presence of CFH-Ab is strongly associated with the lack of 
the CFHR1 gene and protein. Absence of CFHR1 is most often due to a genomic 
deletion, including the CFHR3 and CFHR1 genes, because of nonallelic homologous 
recombination. The gene cluster on the long arm of chromosome 1 (1q32) that 
comprises the CFH and the five CFHR genes in tandem arrangement is prone to 
rearrangements and misalignments, since these genes arose via several segmental 
duplications. 
The CFHR3-CFHR1 deletion is common in the normal population, with varying 
frequencies in the different ethnic groups (e.g., ~2% in Caucasians and ~16% in 
certain African populations, up to ~33% in Nigerians) [54,55]. The delCFHR3-CFHR1 
occurs in ~84% of those aHUS patients with CFH-Ab [23,26,27,30,31]. Thus, the 
development of CFH-Ab is not universally associated with homozygous CFHR1 
deletion, and a significant autoantibody response to CFH can develop in the 
presence of normal CFHR1 [27,31,53]. 
In addition, CFHR1-deficiency caused by mutation in CFHR1, CFHR1-CFHR4 
deletion, and combined CFHR3-CFHR1 and CFHR1-CFHR4 deletions have been 
identified in autoantibody positive patients [26,27,31]. The common feature of these 
various gene deletions is the frequent homozygous deletion of the CFHR1 gene. 
CFH-Ab are also described in patients with additional CFH, C3, MCP and CFI 
mutations [27].  
At the moment, there is only speculation regarding the association of CFHR1 deletion 
with CFH-Ab. Since the C-terminal domains of the two proteins are almost identical, it 
is likely that CFHR1 expression is needed to induce/maintain tolerance against CFH. 
Because the CFHR1 deletion is rather common among healthy individuals, other 
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genetic factors, such as specific HLA alleles, are likely to be additional predisposing 
factors to autoimmune aHUS.  
 
Environmental factors in CFH-Ab HUS 
In addition to genetic factors, environmental factors are apparently important in the 
pathogenesis of CFH-Ab HUS. An infectious event often precedes the manifestation 
of CFH-Ab HUS, although no specific pathogen has been identified [34,35]. Possibly 
CFH acquisition by invading pathogens, a common complement evasion strategy 
[56], may increase the likelihood of break of tolerance to CFH in the context of 
infection particularly in CFHR1-deficient individuals. 
A recent report describing CFH-Ab HUS in Indian patients revealed that among this 
population the autoantibody-associated form is clearly more frequent (~56%) [35] 
compared with previously reported European patient cohorts (~6-25%) [22,23,27,31]. 
This suggests that either the different genetic background of the various ethnic 
groups influences disease manifestation or this is due to environmental factors (such 
as infections), life style differences (such as difference in diet, hygiene and the gut 
microbiom), or the concurrence of these factors. In the same study [35], 4 of 21 
asymptomatic siblings with homozygous deletion of CFHR1 showed high antibody 
titers without any clinical signs of complement activation. This is a striking finding and 
a further follow up of those siblings with CFH-Ab monitoring and further 
characterization of the CFH-Ab is of high importance for our understanding of this 
aHUS disease group, as this finding may question the pathophysiologic role of CFH-
Ab in a subgroup of HUS patients. Further studies are required to define the role of 




Binding sites of the autoantibodies 
Several research groups analyzed the binding sites of the autoantibodies in different 
patient cohorts. In all of these studies, a major autoantibody-binding site was 
identified in the C-terminal SCRs 19-20 of CFH [25,27,29,52]. SCRs 19-20 of CFH 
are responsible for target discrimination, such as recognition and binding to host cells 
expressing surface-associated glycosaminoglycans (Figure 1). Additional binding 
sites in SCRs 8-11 [23], SCRs 1-4 and SCRs 8-15 [27] were reported in a few 
patients. In a few cases, antibody binding only to SCRs 1-4 or 8-15 was found and 
some autoantibodies bound only to full-length CFH but not to the tested fragments 
[27]. Recently, analysis of serum samples from the acute phase of the disease 
revealed polyclonal antibodies binding to several parts of CFH, in many cases 
including the N-terminal complement regulatory domains, and also the C-terminal 
recognition domains and the middle part of the molecule [52].   
In addition to CFH, autoantibodies often cross-react with CFHR1 [27,52,53], due to 
the sequence homology of CFHR1 to CFH, and some antibodies also recognize 
CFHR2 [52]. In contrast, no autoantibody cross-reactivity with CFHR3 and CFHR4 
was reported [53].   
 
Effects of the autoantibodies on CFH function 
The functional effect of the autoantibodies was studied using IgG fractions derived 
from the plasma of patients. Patient-IgG caused impaired binding of CFH to its 
ligands C3b, C3c, C3d, and pentraxin 3 (PTX3) [25,52,57]. As a consequence, 
autoantibodies inhibited the complement regulatory activity of CFH [22,52,57]. In 
addition, hemolysis assays using CFH-Ab positive patients’ plasma and non-
sensitized sheep erythrocytes demonstrated reduced protection of these host-like 
 9
cells from complement-mediated lysis due to inhibition of CFH [25,29,52,53]. These 
functional effects suggest a pathogenic role of the autoantibodies in CFH-Ab HUS. 
Regarding CFHR1, besides impairing the interaction of CFHR1 with PTX3, no effect 
on CFHR1 function was reported [57]. However, CFHR1 may act as a decoy and 
neutralize the autoantibodies [53].   
 
Clinical and laboratory characteristics of CFH-Ab HUS patients 
CFH-Ab HUS has been reported mainly but not exclusively in children [34]. Looking 
at the pediatric cohorts, the age of onset is significantly different from the age usually 
reported in pediatric aHUS, which occurs primarily before the age of 2 years (70%) 
[2], whereas CFH-Ab HUS onset in pediatric cases peaks between 5-12 years with a 
mean age around 8 years [27,31,34,35]. 
Table 1 summarizes the data of the 6 biggest CFH-Ab HUS cohorts 
[27,31,34,35,58,59] published so far regarding the clinical aspects of CFH-Ab HUS. 
The presented data make clear that CFH-Ab HUS is a severe, multisystemic disease 
with a highly relapsing disease course. Moreover, all studies show significant 
percentages of patients presenting with gastrointestinal symptoms and/or diarrhoea, 
thus, resembling eHUS [1]. In addition, all studies highlight the importance of 
infectious triggers, even infections with enterohaemorrhagic Escherichia coli may be 
a trigger of CFH-Ab HUS (Innsbruck HUS study group, personal observation). 
In general, CFH-Ab HUS is characterized by a highly relapsing course (27-58%, 
Table 1) especially in the first two years after disease onset (Innsbruck HUS study 
group, unpublished data) with progression to end-stage renal disease (ESRD) in 20–
35% and a mortality rate of 10% [34]. In the published cohorts, dialysis rates from 17-
74% are described (Table 1). Together with chronic kidney disease (CKD) and 
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ESRD, arterial hypertension is the most frequent complication in patients with CFH-
Ab HUS (13-100%; Table 1). 
Extrarenal complications in CFH-Ab positive HUS during the first flare of disease are 
common, although CNS involvement was found in a significantly lower percentage 
than in CFH-Ab negative patients in 3 cohorts (11%/17%/23% vs. 38%) [31,34,59], 
the biggest published cohort describes initial CNS involvement in 40% [35] of the 
CFH-Ab HUS patients. 
Acute and chronic cardiovascular events, such as cardiac insufficiency [34], 
myocarditis [26], ischemic changes and gangrene in fingers and toes [60], have been 
reported in about 10% of aHUS patients with either adult [58] or pediatric onset [2]. 
Particularly patients with CFH mutations [58] or CFH-Ab [26,34,60] seem to be 
susceptible to develop cardiovascular disorders. 
The presence of CFH-Ab was found to be associated with a lower platelet nadir at 
disease onset compared to CFH-antibody negative patients [31,34]. Initial 
presentation of Stx-negative HUS with severe thrombocytopenia in about 6-10 year 
old patients is especially suspicious for CFH-Ab HUS [31]. The platelet nadir is close 
to the mean platelet nadir in ADAMTS13 activity deficient thrombotic 
thrombocytopenic purpura patients, which may lead to diagnostic difficulties [31]. 
Plasma C3 concentration is decreased in 23 to 67% of patients with CFH-Ab HUS 
(Table 1), and is lower in patients with high titers of anti-CFH IgG than in those with 
moderate titers [34]. CFH plasma concentration was decreased at disease onset in 
22% of patients studied by Dragon-Durey et al., and it did not correlate with anti-CFH 
IgG titers [34]. 
CFH-Ab titers were significantly higher during disease activity than during remission, 
but may increase again when an adequate triggering event is present [31,34,35]. 
Thus, repeated measurements in these patients are recommended to recognize a 
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possible recurrence as early as possible. Due to a high variability between patients, 
CFH-Ab titers can only be interpreted individually [31,34,35]. Moreover, CFH-Ab titers 
may spontaneously decline over time [27,31,34,35] and may even disappear in 
several patients without specific treatment (Innsbruck HUS study group, personal 
observation).  
To date, the influence on the clinical presentation and further disease development of 
additional mutations, the role of the homozygous CFHR1/3 deletion (up to 10% of 
CFH-Ab patients do not show this deletion), the different CFH-Ab binding sites, the 
presence of polyclonal CFH-Ab and the role of the free vs. bound CFH-Ab fraction 
remains unclear and urgently needs further studies. 
 
Therapy of CFH-Ab HUS 
Up to now, there are no consensus guidelines on the treatment of CFH-Ab HUS. As 
for all other aHUS forms, the rationale behind different treatment strategies is the 
normalization of AP regulation. Thus, plasma exchange (PE) using fresh frozen 
plasma (FFP) or virus inactivated pooled plasma, to remove the antibodies and 
enhance the CFH pool, is still the first line induction treatment in CFH-Ab HUS, 
although strategies including the use of the complement C5 blocker eculizumab are 
emerging (discussed in the next section).  
However, antibody titer often reincreases after PE cessation and relapses of HUS 
frequently occur. On the other hand, complications of ongoing plasma therapy are 
multiple, especially primary and secondary treatment failure, allergic reactions and 
vascular access-related infections or thrombosis reduce disease prognosis and 
quality of life significantly [61]. Thus, patients with CFH-Ab HUS may benefit from a 
PE-free maintenance strategy. One major goal for an adequate maintenance therapy 
is the prevention of ongoing CFH-Ab production and thus disease recurrences. 
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Therefore, initiation of maintenance immunosuppressive/immunoregulatory treatment 
is recommended, using steroids, azathioprine, mycophenolate mofetil (MMF), 
intravenous cyclophosphamide, anti-CD20 and/or intravenous immunoglobulins 
(IVIG) [28,31-43]. The duration of plasma therapy (PT), in particular applied as PE 
and the choice of the immunosuppressive drug are presently not standardized. Both 
should be guided by the evolution of CFH-Ab titer. High antibody titer is correlated 
with the risk of relapses, which in turn increase the risk of renal sequelae [31,34,35].   
In the largest reported series [34,35] induction therapy using PE directly followed by 
early maintenance therapy using immunosuppressants had a favourable outcome. 
Table 2 summarizes published case series and case reports regarding treatment and 
outcome of CFH-Ab HUS patients, excluding the two biggest cohorts [34,35], 
discussed in detail below. The summary of published case series shows the 
heterogeneity of therapeutic strategies used. Nevertheless, PE is the preferred 
therapy option at disease onset and the majority of patients received a maintenance 
therapy. Patients with conservative therapy (no PT, complement targeting or 
immunosuppressive treatment) alone and patients without an initial maintenance 
therapy showed a high rate of ESRD (Table 2). 
From the French cohort [34] consisting of 45 CFH-Ab HUS patients treatment 
modalities and the outcome of 30 CFH-Ab HUS patients were documented. Six of the 
thirty patients were treated conservatively with the following disease evolution of the 
first flare: 1/6 without sequelae, 1/6 with CKD, 2/6 with late relapses (>1 month after 
onset and >15 days after remission), 1/6 with ESRD and 1/6 without any signs of 
remission. 6/30 patients were treated with plasma infusion (PI) as induction therapy, 
five of those presenting with late relapses and one with therapy resistance. Fifteen of 
the 30 patients were treated with PE initially, one without any sequelae, three with 
CKD, six with late recurrences, one with initial ESRD, three were treatment resistant 
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and one patient died. Three out of thirty received PE plus immediate 
immunosuppression, 2 using oral prednisolone and cyclophosphamide, one using 
MMF; none of those patients showed any sequelae, all responded to therapy and 
showed complete remission. IVIG was administered in 15 patients but did not show 
any benefit in the published cohort. However, IVIG were administered in combination 
with PE or steroids and details of timing and dosage were not discussed. In one out 
of two patients use of rituximab during recurrence was successful, in the other it 
failed to show any benefit. 
The biggest published CFH-Ab HUS cohort [35] so far, describes 138 CFH-Ab HUS 
patients, including information on therapy and outcome. One hundred and five of the 
138 patients were treated with PE initially, 15 received 2-10 PI; for 26 patients with 
high CFH-Ab titers and/or delayed hematologic remission IVIG was given 
additionally. In 87 patients immunosuppression as induction therapy was started 
27±21 days after disease onset. All of those patients received oral prednisolone, in 
49 patients combined with cyclophosphamide and in 18 patients combined with 
rituximab. A further maintenance immunosuppression regimen was given to 47 
patients, all receiving oral prednisolone, in 18 patients in combination with MMF and 
in 8 patients in combination with azathioprine. 
Combined therapy with PE and induction immusuppression showed significant 
improved renal survival rates compared to patients not receiving combined treatment. 
(83% vs 46% at 6 months and 71% vs 33% at last follow up). Furthermore, 
maintenance therapy with immunosuppressive agents significantly lowered 
probability of disease relapse.  
Irrespective of the different therapeutic strategies, a relapse-free survival was 
documented in 89% after 6 months, 85% after 12 months and 73% at last follow up. 
After 3 months 8% showed CKD stage I with normal urine analysis, 43% CKD stage I 
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with hypertension, hematuria and/or proteinuria, 20% showed CKD stages II-III and 
30% CKD stages IV-V. Determinants of adverse outcome were a high peak 
creatinine, high CFH-Ab titers at onset, low C3, delayed hematologic remission, need 
for prolonged dialysis, acute cortical necrosis in the biopsy and time to PE ≥ 17 days.   
The authors concluded that delayed initiation of PE (2-3 weeks beyond onset) 
predicted adverse outcomes. Differences between types of immunosuppression were 
not investigated in this study. Maintenance immunosuppressive therapy reduced the 
risk of relapses by 91%. The use of immunosuppression prevented one relapse in 
about 5 patients (number needed to treat), thus maintenance immunosuppression 
appeared to be a more feasible and successful strategy for preventing relapses, than 
prolonged/chronic PE. 
All in all, this study demonstrated the long term benefits of an early induction therapy 
using PE and immunosuppressive agents followed by an immunosuppression-based 
maintenance regimen. 
However, CFH-Ab patients with additional mutations in complement regulatory 
proteins other than CFHR1/3 are thought to be at a higher risk for ongoing 
complement activation and disease activity despite an early and adequate 
immunosuppressive regimen [27,39]. Until now we lack data on the effect of 
additional mutations on CFH-Ab HUS patients’ therapy and outcome. 
  
Eculizumab in CFH-Ab patients 
Eculizumab was shown to effectively block the terminal complement cascade by 
preventing the cleavage of C5 whose pivotal role in complement-HUS pathogenesis 
was demonstrated in murine models [62,63]. Eculizumab is approved for the use in 
atypical HUS, its safety and efficacy was shown in two clinical trials, recently 
published [64]. Most recent reviews come to different conclusions concerning the use 
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of eculizumab in CFH-Ab HUS patients and do not address the threefold possibility 
for applying eculizumab, i.e., the possible use for induction during acute phase, for 
maintenance therapy or during relapses [65-67].  
Noone et al. [39] report the successful use of eculizumab in two patients with CFH-Ab 
HUS and a homozygous CFHR1/3 deletion without additional complement mutations. 
The first patient presented with a PI dependent course, and was switched in stable 
condition to eculizumab therapy 4 years after initial disease presentation. CFH-Ab 
titers remained low despite ongoing signs of complement activation, creatinine 
showed a stable course and there were no signs of disease recurrence, as already 
documented under PI maintenance therapy. Thus this case lacks evidence for a 
disease improving effect of eculizumab, despite demonstrating a safe weaning from 
chronic PI under eculizumab four years after disease onset. The second patient 
(homozygous CFHR1/3 deletion, no additional complement mutations) showed a PE 
responsive disease course and was switched to eculizumab 16 days after disease 
onset due to allergic reactions. Four days after eculizumab initiation his C3, 
creatinine and platelets normalized. During the further disease course C3 decreased 
again and stayed low. For this patient follow-up data of only 11 weeks are presented, 
which is a limitation for the interpretation of the therapeutic effect. 
Whether eculizumab is reasonable as induction therapy replacing PE for CFH-Ab 
HUS patients is still under debate; initial abdication of eculizumab in the treatment of 
CFH-Ab HUS may even nowadays be justified, as aggressive PE, followed by 
maintenance therapy with immunosuppression was shown to be a good treatment 
option for CFH-Ab associated HUS patients [28,31-43]. On the other hand, for CFH-
Ab HUS patients with additional complement regulatory protein mutations eculizumab 
therapy for induction and maintenance may be of benefit compared to an exclusive 
immunosuppressive strategy [27,39].  
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Although only very few data on the use of eculizumab in CFH-Ab HUS patients exist 
thus far [39,65-68], in contrast to data on PE combined with immunosuppression, its 
use as initial induction therapy or during recurrences may be justified in patients with 
CFH-Ab and additional complement mutations and for patients where initial PE is not 
feasible or patients do not respond. The use of eculizumab as maintenance option is 
questionable.  
Controlled studies comparing the combination of early PT and immunosuppression 
with eculizumab based therapeutic strategies are urgently needed. In addition, other 
complement inhibitors are being developed, such as those inhibiting complement at 
the level of C3 [69], which may be another treatment option in the future. 
Figure 2 details the authors recommendation for the therapy of CFH-Ab HUS patients 
based on the data presented in this review. 
 
Transplantation and CFH-Ab 
The risk of post-transplant recurrence in patients with CFH-Ab HUS is not well 
documented. Altogether 17 CFH-Ab HUS patients undergoing 25 renal 
transplantations are reported in the literature [26,27,32-35,40,41,58,70] (Table 3). 
HUS recurrence was described for six grafts, leading to graft loss in three. Two grafts 
(from 1 patient) were lost due to chronic allograft nephropathy. 
For 8/25 transplantations a specific prophylactic pre-transplant treatment was 
performed, 7 of eight renal transplantations (RT) showed a favourable outcome 
without recurrence and a TMA episode was observed in one graft, showing a 
favourable outcome after initiation of eculizumab therapy.  
It is suggested that recurrence can be expected if a high CFH-Ab titer persists at the 
time of transplantation, thus a pre transplant procedure to reduce CFH-Ab is 
reasonable and, on the basis of the above mentioned data, recommended. Those 
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prophylactic therapies should include PE at least prior to transplantation; whether 
further prophylactic interventions are necessary (rituximab, IVIG) remains unclear 
and has to be decided on an individual basis. Nevertheless, recurrence free 
transplantation was achieved in patients with CFH-Ab without any specific treatment 
as well (Table 3). However, pre-transplant screening of CFH-Ab titers was not 
available in these cases.  
The evaluation of post-transplant recurrence risk is hampered by the fact that a 
significant proportion of CFH-Ab HUS patients carries mutations in CFH, CFI, MCP or 
C3 [27] and that up to now it is unclear whether patients with CFH-Ab HUS and 
homozygous CFHR1/3 deletions (in some publications denoted as DEAP HUS 
patients [40,71]) behave different than patients with CFH-Ab without such a deletion. 
Six out of 9 transplanted CFH-Ab HUS patients showed a homozygous CFHR1/3 
deletion. Four out of 10 transplanted CFH-Ab HUS patients who underwent further 
genetic screening showed alterations: C3 mutation (n=1), CFH mutation (n=1), CFH 
variant (n=1) and CFI polymorphism (n=1) (Table 3).  Thus, the available data in the 
literature do not allow a final conclusion on that issue. Nevertheless, it seems 
reasonable to treat patients with CFH-Ab HUS and additional mutations, especially 
CFH mutations, as high-risk patients.  
Recently published recommendations [65,70], point towards a differentiation of CFH-
Ab HUS patients prior to renal transplant in low, moderate and high-risk patients 
concerning recurrence after renal transplantation. Patients with low risk of recurrence 
are those with long term negative CFH-Ab titers and without additional complement 
mutations. Those patients are currently not thought to benefit from a prophylactic 
therapy before renal transplant. Patients with persistent low CFH-Ab titers and 
without additional mutations are recommended to be treated with either prophylactic 
PE or prophylactic eculizumab, the decision depends on the availability of an 
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adequate vascular access and/or the availability of eculizumab. It remains to be 
shown whether CFH-Ab HUS patients with high CFH-Ab titers but without additional 
complement mutations belong to the high-risk group. For CFH-Ab HUS patients with 
additional mutations we recommend prophylactic eculizumab therapy prior and 
immediately after transplantation. The optimal time point for weaning of eculizumab 
remains to be determined and depends on the clinical presentation of the patient, the 
graft, CFH-Ab titers and complement activation split products. To address the latter 
we recommend monitoring of C3, preferably activation split products such as C3d, or 
SC5b-9. It is likely that on the long run the immunosuppressive regimen for 
transplanted children may be sufficient for an ongoing inhibition of CFH-Ab 
production; nevertheless, the transplant procedure itself may serve as a strong 
trigger for complement activation, but also for CFH-Ab production. 
 
Concluding remarks 
Early and accurate CFH-Ab testing using appropriate assays is the key step, as early 
induction of plasma exchange and concomitant immunosuppression lead to a 
favourable outcome in those patients. 
Although there is no sufficient data on the use of eculizumab in CFH-Ab HUS 
patients thus far, its use as initial induction therapy or during recurrences may be 
justified in patients with CFH-Ab and additional complement mutations and for 
patients where initial PE is not feasible or patients are not responding. Eculizumab for 
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monoclonal antibodies; MCP, membrane cofactor protein; MMF, mycophenolate 
mofetil MPGN, membranoproliferative glomerulonephritis; PE, plasmaexchange; PI, 
plasma infusion; PT, PE and/or PI; PTX, pentraxine; RT, renal transplantation; SCR, 
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Legends to tables and figures 
Table 1 title: Summary of clinical data of the six biggest CFH-Ab HUS cohorts 
published.  
Table 1 legend: Card.: cardial complications; CNS: central nervous system; D+: 
diarrhea positive; GIT: gastrointestinal Symptoms; Hypert.: arterial hypertension; 
Mut.: mutations; N: number; n/a: not applicable; Panc.: pancreas; Rec.: recurrence; 
Ref.: reference; RTI: respiratory tract infection;  Vasc.: vascular defects; y: years 
 
Table 2 title: Current therapy reports on CFH-Ab HUS patients. Excluding references 
35 and 36, which are discussed in detail in the text.  
Table 2 legend: AZA: azathioprine; CKD: chronic kidney disease; CNS: central 
nervous system; conservative treatment: no complement targeted therapy, PT or IS; 
CPH: cyclophosphamide; CyA: cyclosporine A; ECU: eculizumab; ESRD: end-stage 
renal disease; IS: immunosuppression; IVIG: intravenous immunoglobulins; MTP: 
methylprednisolone; MMF: mycophenolate mofetil; N: number; n/a: not applicable; 
PE: plasma exchange; PI: plasma infusion; Pred.: prednisolone; PT: plasma therapy 
(PE and/or PI); Rec.: recurrence; Ref.: reference; RTX: rituximab; TMA: thrombotic 
microangiopathy; TX transplantation;  
 
Table 3 title: Cases of transplanted CFH-Ab HUS patients and their outcome reported 
in the current literature.  
Table 3 legend: ATG: anti thymocyte globuline; AZA: azathioprine; CFHR: 
complement factor H related protein; conservative treatment: no complement 
targeted therapy, PT or Immunosuppression; CyA: cyclosporine A; ECU: eculizumab; 
ESRD: end-stage renal disease; Gen.: genetics; IVIG: intravenous immunoglobulins; 
MMF: mycophenolate mofetil; n/a: not applicable; nTx: number of transplantations; 
 29
p.c: personal communication; PE: plasma exchange; PI: plasma infusion; polym.: 
polymorphism; Pred.: prednisolone; PT: plasma therapy; rec.: recurrence; Ref.: 
reference; RTX: rituximab; sequ.: sequencing; TMA: thrombotic microangiopathy; Tx: 
transplantation; 
 
Figure 1 title: Schematic structure of factor H and representation of CFH binding to 
C3b. 
Figure 1 legend: The schematic structure of complement factor H (CFH). (A) CFH is 
composed of 20 short consensus repeat (SCR) domains, of which the four N-terminal 
domains (SCRs 1-4) mediate the complement inhibiting effect of CFH and the two C-
terminal domains (SCRs 19-20) mediate CFH binding to host cells. (B) Schematic 
representation of CFH binding to C3b deposited on a host cell surface. 
 
Figure 2 title: Recommendation for the treatment of CFH-Ab HUS. 
Figure 2 legend: ECU: eculizumab; PE: plasma exchange; IS: immunosuppression; 
At onset of suspected aHUS the underlying cause is unclear. Thus, the current 
recommendations point towards an early implementation of eculizumab therapy till 
the diagnosis is made. Alternatively, early PE therapy is possible. If CFH-Ab 
screening is positive two treatment options are reasonable. On the one hand a 
further ECU therapy with additional IS therapy (this treatment arm will be preferred 
for patients where ECU was already started before CFH-Ab diagnosis) and on the 
other hand a further PE therapy with additional IS agents. For patients with PE 
resistance (no hematological response after 5 daily sessions) or complications a 
switch to ECU is recommended. Although no evidence based data are available, it is 
reasonable that ECU or PE therapy can be stopped/weaned after reaching complete 
or hematologic remission. However, a further maintenance immunosuppression is 
 30
important combined with an individual CFH-Ab titer follow up. The duration of an 
optimal maintenance therapy remains to be determined. If CFH-Ab titers are 
persistently at a low range or negative and the patient had no signs of recurrence, 
weaning of IS therapy after 1-2 years on an individual basis seems reasonable. The 
optimal kind of IS is currently not established. We recommend the initiation of 
mycophenolate mofetil (MMF) with an AUC goal of >40mg/lh. If MMF fails to be 
sufficient, addition of oral prednisolone or a switch to Cyclophosphamide plus oral 













































35 138 (8y) n/a 9% n/a 66% 42% 40% 57%// 41% 59%
1.4%
N 2 30% 62000 62% 7054 27% n/an a =
34 45 (9y) 84% 53% n/a 68% 28% 23% 50%/23% 27% n/a
6.7%
N=3 57% 56000 58% 11564 58% 0/26
31 25 (8 y) 87% 13% 42% 59% 50% 11% n/a n/a n/a n/a 74% 30000 41% 1342 n/a 1/8
27 13 (8y) n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 23% n/a n/a 5/13
58 10 (n/a) n/a 13% 50% 13% n/a n/a n/a n/a n/a n/a n/a n/a 43% n/a 37% 2/10
59 6 (n/a) 83% n/a 50% 100% 50% 17% n/a n/a n/a n/a 17% 50000 67% n/a 50% 2/6
Ref N Treatment at Onset Maintenance For Recurrence Outcome at last follow up (years) – Transplantation (TX)




Remission ‐ 9 weeks after onset
change to PE+PI
None till 1st rec. After 1st rec.: PI –
sustained remission over 4y, 
switched to ECU after 4y
1st: 2 weeks after remission PI + oral 
Pred Complete remission
   
1 PP – complete remission PP – allergic reaction – PP switched to ECU No rec. Complete remission
36 37




2nd: PE+CPH+Pred. Complete remission (6y)
PI – no remission, 1  PE + 2 CPH pulses ‐ remission Oral Pred over 6 months No rec. Complete remission (4y)
2 PE + 2 CPH pulses ‐ remission Oral Pred over 6 months No rec. Complete remission (4 months and 4y)
43 1 PE ‐ remission
None till 1st rec., after 1st rec: 
oral Pred. + AZA + PI; AZA 
switched to CyA and to MMF
1st rec.: 1 month after remission: PE –
no remission – PE+MTP Pulse+CPH
CKD IV after 20 months
CNS‐Sequelae
41 1 PE – partial remission none PE for rec. after 8 weeks ‐ ESRD ESRD after 8 weeks; succesfully transplanted after 74 weeks with basiliximab, Pred. and MMF; Favorable outcome with negative CFH‐Ab titers 6 ½ y after Tx
59
3 PE – partial remission PT PE 3/3 Hypertension
1 PE – partial remission none n/a 1/1 Hypertension






Complete remission (2, 3  and 6y)
10 C ti Conservative 6/10 with ESRD, 3/10 transplanted; Transplanted patients without Rec. ;onserva ve none Complete remission at last follow up in 4 patients (3‐11 y)
58 8 3/8 PE + Steroids – 2 remissions n/a n/a
75% of TMA episodes responsive to PT, 25% complete remission, 50% partial 
remission; after 3y  1/8 in complete remission and 2/8 in partial remission; 1/8 
transplanted – with graft lost due to rec.; 5/8 ESRD or death after 3y






           
with PI and oral Pred.), and 10y (PE, maintenance with AZA); 3/7 ESRD (2 with
conservative treatment 1 with PE alone)
1/7 Death (myocarditis at initial episode)
68 1 ESRD before treatmentPE – hematologic remission none
1 rec. including nonspecific skin
vasculopathy – treated with Ecu ‐
remission
ESRD
Hematologic remission after 1st rec.
32,33 2 Conservative None None
1: ESRD after onset – 5 times transplanted; before last Tx diagnosis of CFH‐Ab; 
Succesfully last transplant under PI and PE
2: ESRD 2 month after onset; oral Pred. + AZA + RTX+PE prior Tx, PE for 4 
months after Tx – no rec. 2 years after Tx
28
1
PE – ongoing hemolysis at day
18 + IVIG and start with oral  After 1st rec.: Oral Pred. + AZA 1st rec. at day 58: PE Complete remission
Pred.
2 PE PI+oral Pred. None Complete remission (1y)
40
1 PI – partial remission with ESRD None No rec. ESRD – successfully transplanted after publication







1st rec.: 4 month after remission –
treated with PE
2nd rec.: 3 months after remssion –
treated with PI without success ‐ PE
ESRD
1 PE – remission Oral Pred. + MMF No rec. Complete remission (2y)
1 PE ‐ remission PI No rec. CRI III 7.5y after onset
Ref N (Age onset
/1st Tx)
Gen. nTx Disease course prior Tx Treatment prior Tx Tx Outcome
35 3 (n/a) n/a 1 n/a 4‐6 sessions PE (n=2)Perioperative IVIG+RTX (n=2)
Living‐related (n=2)
Cadaveric (n=1)
At 6‐15 months post Tx all patients with
satisfactory graft function and CFH‐Ab levels
betwen 180‐430 AU/ml
27
1 (10/12) CFHR1/3C3 mutation 1
Initially conservative
treatment followed by ESRD n/a n/a 3 years after Tx no rec.
1 (6/11) No CFHR1/3no further mutation 1
Initially conservative
treatment followed by ESRD n/a n/a 2 years after Tx no rec.
1 (10/12) CFHR1/3 1 Initially conservative / / 6 years after Tx no rec.  CFH mutation treatment followed by ESRD n a n a
34
1 (n/a) n/a 1 n/a PE + RTX n/a Favorable after 8 months
2 (n/a) n/a 1 n/a n/a n/a
Tx with undiagnosed CFH‐Ab; both with post‐
Tx recurrence; CFH‐Ab disapeared in both 42 






1 Initially conservativetreatment followed by ESRD n/a n/a
At the age of 20 years still functioning graft, no
comments on recurrences
1 (3/4) No deletions ort ti 1
Initially conservative
t t t f ll d b ESRD n/a n/a
Functioning graft at last follow up (8 months
ft T )mu a ons rea men o owe y a er  x
32 1 (10/12.5) CFH sequ. normalRest n/a 1
Initially conservative







(switched to Tac‐ at month 18 
post Tx), MMF
no rec. And favorable outcome 2 years after Tx
1st Tx lost due to recurrence 15 days after Tx;






already before 4th transplant;
         
2nd and 3rd Tx lost after 13 and 11y  due to
chronic allograft nephropathy;  4th graft lost 
after 1y due to TMA; 5th graft with favorable 
outcome at last follow up (4y)
70 1 (6/n/a) CFHR1/3 5 n/a Incomplete response to n/a
5 y post 5th Tx TMA lesions in biopsy performed
because of decrease in renal function; start
  prophylactic PE ; with ECU followed by stabilization of serum
creatinine ;
41 1 (9/11) CFHR1/3CFH variant G2850T 1
PE followed by recurrence –
again PE followed by ESRD 2h prior Tx Basiliximab
Cadaveric; 4 days post Tx again
Basiliximab; IS with Pred. And
MMF
6 ½ years after Tx favorable outcome with
negative CFH‐Ab titers
58 1 (n/a) n/a 1 n/a n/a n/a Graft loss due to recurrence






detectable at low titer (p.c Hofer J.)
